DIRECT, SIMPLIFIED, AND SENSITIVE ASSAY OF ANGIOTENSIN-II IN PLASMA EXTRACTS PERFORMED WITH A HIGH-AFFINITY MONOCLONAL-ANTIBODY

被引:0
作者
SIMON, D
ROMESTAND, B
HUANG, HM
BADOUAILLE, G
FEHRENTZ, JA
PAU, B
MARCHAND, J
CORVOL, P
机构
[1] FAC PHARM MONTPELLIER, IMMUNOL LAB,CNRS,UMR 9921, MONTPELLIER 1, FRANCE
[2] CNRS, CTR PHARMACOL,INSERM, F-34033 MONTPELLIER, FRANCE
[3] COLL FRANCE, INSERM,U36, F-75231 PARIS 05, FRANCE
[4] UNIV MONTPELLIER 2, F-34060 MONTPELLIER, FRANCE
关键词
HYPERTENSION; RADIOIMMUNOASSAY; HPLC COMPARED; CAPTOPRIL; ANGIOTENSIN-CONVERTING ENZYME;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
A very simple, fast, and sensitive RIA of angiotensin (Ang) II has been developed, based on a monoclonal antibody with high affinity and specificity, making possible the direct measurement of circulating Ang II in human plasma after solid-phase extraction. The purified monoclonal antibody 4D8 has an association constant of 1.3 x 10(11) L/mol with Ang II and a cross-reactivity of < 1 % for Ang I. The assay can detect as little as 0.8 fmol of Ang II in 2 mL of plasma and is not influenced by the presence of Ang I. Analytical recoveries between 112% and 116% were obtained for Ang II added to human plasma at physiological concentrations. Comparison of the RIA with a reversed-phase, high-performance liquid chromatographic method followed by RIA to measure Ang II in human plasma samples from normal and hypertensive subjects and from normotensive subjects before and after an acute inhibition of angiotensin-converting enzyme with captopril (50 mg)-showed a high degree of correlation (r2= 0.93) between the two methods.
引用
收藏
页码:1963 / 1967
页数:5
相关论文
共 1 条
  • [1] PHARMACOLOGY OF XR510, A POTENT ORALLY-ACTIVE NONPEPTIDE ANGIOTENSIN-II AT(1) RECEPTOR ANTAGONIST WITH HIGH-AFFINITY FOR THE AT(2) RECEPTOR SUBTYPE
    WONG, PC
    QUAN, ML
    SAYE, JM
    BERNARD, R
    CRAIN, EJ
    MCCALL, DE
    WATSON, CA
    ZASPEL, AM
    SMITH, RD
    WEXLER, RR
    TIMMERMANS, PBMWM
    CHIU, AT
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1995, 26 (03) : 354 - 362